Skip to main content
SpringerLink
Log in

The EMA’s Pharmacovigilance Working Party (PhVWP) is recommending an update to the product labelling for rosuvastatin,

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA Pharmacovigilance Working Party (PhVWP).Rosuvastatin and the risk of gynaecomastia. PhVWP Monthly Report: 2, No. 1111, 24 Nov 2011. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The EMA’s Pharmacovigilance Working Party (PhVWP) is recommending an update to the product labelling for rosuvastatin,. React. Wkly. 1385, 5 (2012). https://doi.org/10.2165/00128415-201213850-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213850-00008

Keywords

Search

Navigation